Catalog No.
Product Name
Application
Product Information
Citations
-
Antipsychotic Agent
Piquindone is a potent antipsychotic agent that primarily targets the D2 dopaminergic receptor subtype, exhibiting sodium-dependent binding characteristics. This compound demonstrates significant biological activity relevant to the modulation of dopaminergic signaling and is utilized in research focused on schizophrenia and related neuropsychiatric disorders. -
D3 Receptor Antagonist
Dopamine D3 receptor ligand-6 is a selective antagonist of the dopamine D3 receptor. This compound is valuable for investigating mechanisms involved in substance use disorders, including opioid and psychostimulant addiction. Its specificity for the D3 receptor makes it an important tool in pharmacological studies aimed at understanding and potentially mitigating addiction-related behaviors. -
Dopamine D(3)-Receptor Antagonist
S33084 is a selective antagonist of the dopamine D(3) receptor, exhibiting pKi values of 8.72, 8.62, and 6.82 for cloned rat dopamine D3, native rat dopamine D3, and D2 receptors, respectively. This pharmacological profile indicates its potency and specificity in targeting the D(3) receptor. S33084 is primarily utilized in research focusing on neuropharmacology, aiding investigations into the role of dopamine signaling in various neurological disorders. -
Antidepressant Agent
MeSeI is an antidepressant agent that weakly inhibits monoamine oxidase (MAO) A and B, exhibiting an IC50 value of 198.8 µM. It modulates the activity of dopamine receptor D2 and norepinephrine receptors α2 and β1, demonstrating antidepressant-like effects in animal models. MeSeI is administered orally, making it a convenient candidate for further research into mood disorders and related pharmacological applications. -
Neuroleptic Agent
Fluphenazine decanoate dihydrochloride is a long-acting phenothiazine neuroleptic agent that primarily targets dopamine D2 receptors. It exhibits potent antipsychotic activity, making it valuable for the study of schizophrenia and related disorders. This compound is useful in research aimed at understanding neuropharmacology and the mechanisms underlying psychiatric conditions. -
Dopamine-Blocking Agent
Oxiperomide is an orally active dopamine-blocking agent that primarily targets dopamine receptors. It exhibits significant antagonistic activity, making it useful for studying dopaminergic signaling pathways and related neurophysiological processes. This compound is applicable in research involving neuropsychiatric disorders and the exploration of dopamine's role in various physiological functions. -
Dopamine Uptake Inhibitor
GBR-12879 dihydrochloride is a potent dopamine uptake inhibitor that selectively targets the dopamine transporter. Its primary mechanism involves preventing the reabsorption of dopamine, thus enhancing dopaminergic signaling. This compound is widely utilized in research to investigate the role of dopamine in neurological disorders and to explore potential therapeutic strategies for conditions such as depression and schizophrenia. -
Drug Metabolite
Piribedil N-oxide is a metabolite of the dopamine receptor agonist Piribedil, primarily functioning as a drug metabolite. This compound retains the ability to interact with dopamine receptors, contributing to studies on dopamine signaling pathways and pharmacokinetics. Its characterization is essential for understanding the metabolic fate of Piribedil and its potential implications in neurological research and therapeutic applications. -
Dopamine D4 Receptor Agonist
ABT-724 is a potent and highly selective agonist of the dopamine D4 receptor, exhibiting an EC50 of 12.4 nM for the human receptor. It also demonstrates efficacy as a partial agonist at the rat and ferret D4 receptors, with EC50 values of 14.3 nM and 23.2 nM, respectively. ABT-724 shows minimal activity against dopamine D1, D2, D3, and D5 receptors, making it a valuable tool for exploring the role of the D4 receptor in neurological conditions and potential therapeutic applications for erectile dysfunction. -
Dopamine D2 Receptor Agonist
Quinelorane is a potent dopamine D2 receptor agonist. It has been shown to facilitate semen ejaculation while inhibiting penile erection in rat models. This compound is valuable for investigating mechanisms underlying sexual dysfunction and related therapeutic approaches. -
Stable Isotope
Molindone-d8 is a deuterated form of the antipsychotic agent molindone, primarily used as a stable isotope in scientific research. Its primary mechanism involves dopamine receptor antagonism, reducing the effects of dopamine and helping to mitigate symptoms of schizophrenia. This labeled compound is particularly valuable in pharmacokinetic studies and metabolic research, allowing for precise tracking and analysis of drug behavior in biological systems. -
Stable Isotope
Ropinirole-d3 is a deuterated analog of Ropinirole, primarily targeting D3 and D2 dopamine receptors. As a potent agonist, Ropinirole exhibits a Ki value of 29 nM for the D2 receptor, alongside pEC50 values of 7.4, 8.4, and 6.8 for human D2, D3, and D4 receptors, respectively. This stable isotope is useful in pharmacokinetic studies and can provide insights into the mechanism of action related to dopaminergic therapies, particularly in the context of Parkinson's disease research. -
Bisbenzylisoquinoline Alkaloid Secoderivative
S-Secoantioquine is a bisbenzylisoquinoline alkaloid secoderivative that primarily targets dopamine receptors. It exhibits weak displacement activity on the 3H-SCH 23390 binding site and demonstrates certain displacement activity on the 3H-raclopride binding site in rat striate membrane experiments. This compound is useful for research in neuropharmacology and may aid in understanding the mechanisms of dopaminergic signaling. -
D3 Receptor Agonist
PF 219061 is a selective agonist of the dopamine D3 receptor, exhibiting an EC50 of 15 nM. This compound demonstrates rapid absorption and efficient liver blood clearance, making it suitable for studying female sexual dysfunction. Its specificity for the D3 receptor allows for exploration of its potential therapeutic applications in related disorders. -
Dopamine D4 Receptor Agonist
A-412997 is a selective agonist of the Dopamine D4 receptor, exhibiting Ki values of 12 nM for rat and 7.9 nM for human receptors. This compound has been demonstrated to enhance short-term memory and cognitive functions in rodent models, making it a valuable tool for research into psychiatric disorders and cognitive enhancement. Its specificity and potency facilitate studies on the Dopamine D4 receptor's role in neurobiology and medicine. -
Serotonin-Norepinephrine-Dopamine Releasing Agent
4-Bromoamphetamine hydrochloride is a potent serotonin-norepinephrine-dopamine releasing agent (SNDRA) that exhibits significant stimulant effects. This compound plays a crucial role in neurological research, particularly in studies examining neurotransmitter release and potential neurotoxicity. Notably, 4-Bromoamphetamine hydrochloride has been associated with long-term depletion of serotonin, making it relevant for investigations into neurodegenerative conditions and the mechanisms of neurotransmitter regulation. -
Dopamine Receptor-blocking Agent
(±)-Butaclamol hydrochloride is a dopamine receptor-blocking agent primarily utilized in neuropharmacological research. As the (+)-enantiomer of butaclamol, it demonstrates strong binding affinity to dopamine receptors, making it useful for studying dopamine-mediated pathways. This compound is often applied in the investigation of psychiatric disorders and the development of antipsychotic medications. -
Dopamine D2 Receptor Antagonist
ADR 851 is a potent antagonist of the dopamine D2 receptor, known for its role in neurotransmitter signaling. This compound demonstrates significant activity in modulating dopaminergic pathways and has been utilized in research related to antiemetic therapies. Its effectiveness in targeting the D2 receptor makes it a valuable tool for studies investigating the mechanisms of nausea and emesis. -
Dopamine Receptor Agonist
PD-168077 is a selective agonist for the dopamine D4 receptor, exhibiting a binding affinity (Ki) of 9 nM. This compound demonstrates significant biological activity in modulating dopaminergic signaling pathways, making it a useful tool for research focused on neuropharmacology and psychiatric disorders. Its specificity for the D4 receptor allows for targeted studies in areas such as schizophrenia and addiction, facilitating the exploration of therapeutic interventions. -
Dopamine D1 Receptor Agonist
A-86929 functions as a potent and selective agonist for the dopamine D1 receptor, exhibiting a pKi value of 7.3. It has been shown to significantly induce rotational behavior in the 6-OHDA-induced unilateral nigrostriatal lesion rat model and improve motor function in the MPTP-induced Parkinson's disease marmoset model. Additionally, A-86929 may provide therapeutic insights for reducing cocaine-seeking behavior in rat studies and reversing Haloperidol-induced cognitive deficits in rhesus monkeys. This compound is valuable for research focused on neurological disorders. -
Dopamine Receptor Antagonist
(-)-OSU6162 is a potent presynaptic dopamine receptor antagonist, primarily targeting the D2 dopamine receptor subtype. It exhibits inhibitory effects on dopamine release, making it valuable for research on dopaminergic signaling and its implications in neuropsychiatric disorders. This compound is useful for studying the role of dopamine in various biological systems and can aid in the development of treatments for conditions such as schizophrenia and addiction. -
D4 Receptor Antagonist
PD-89211 is a selective antagonist of the dopamine D4 receptor, exhibiting a Ki value of 3.7 nM. It effectively reverses Quinpirole-induced [3H]thymidine uptake in CHOpro5 cells, with an IC50 of 2.1 nM. This compound plays a significant role in regulating dopamine and norepinephrine metabolism in the hippocampus, making it valuable for research into central nervous system disorders, including schizophrenia. -
Dopaminergic Agonist
GYKI-32887 is a selective dopaminergic agonist that primarily targets dopamine receptors. This compound is notable for its ability to reduce motor activity levels in rodent models, making it a valuable tool for studying dopaminergic signaling pathways and motor function disorders. Its application spans across neuropharmacological research, particularly in understanding the mechanisms of drug action in neurological conditions. -
hD2R Activator
Boc-MIF-1-Am is a potent enhancer of the human dopamine D2 receptor, exhibiting an EC50 value of 17.82 nM. This bioconjugate of melanostatin (MIF-1) and amantadine is primarily utilized in the study of dopaminergic signaling pathways and their implications in neurological disorders. Although Boc-MIF-1-Am demonstrates key biological activity, it has been noted to exhibit mild neurotoxicity at a concentration of 200 μM in SH-SY5Y cells, making careful consideration necessary in experimental designs. -
D2 Receptor Agonist
Sumanirole is a highly selective D2 receptor full agonist, exhibiting an ED50 of approximately 46 nM. This compound is significant in the research of Parkinson's disease and restless leg syndrome, providing insights into dopaminergic signaling pathways. Its potent agonistic activity at the D2 receptor makes it valuable for exploring therapeutic strategies in these neurological disorders. -
Dopamine Receptor Control
Aripiprazole N1-oxide is a metabolite of the atypical antipsychotic drug Aripiprazole, produced through the activity of cytochrome P450 isoforms CYP2D6 and CYP3A4. This compound primarily targets dopamine receptors, influencing dopaminergic signaling pathways. Aripiprazole N1-oxide is significant in research related to psychiatric disorders, enabling the study of receptor modulation and metabolic pathways in drug efficacy and safety. -
D1 Receptor Antagonist
rel-Ecopipam hydrobromide is a potent D1 receptor antagonist with a Ki value of 1.30 nM. This compound effectively inhibits dopamine D1 receptor activity, making it a valuable tool for research in neuropharmacology and the study of dopamine signaling pathways. Its unique mechanism of action positions it for investigations into the role of D1 receptors in various neurobiological processes and potential therapeutic targets for neurological disorders. -
Dopamine Receptors Agonist
Dinoxyline is a potent agonist of dopamine receptors, exhibiting high affinity with Ki values of 7 nM, 6 nM, 5 nM, and 43 nM for D1, D2, D3, and D4 receptors, respectively. This compound is valuable for investigating dopaminergic signaling pathways and their implications in neurological research. Its ability to selectively engage dopamine receptors makes it an essential tool for studies related to mood disorders, addiction, and other neurological conditions. -
DAT/NET/SERT Inhibitor
Amitifadine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that targets the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). It exhibits inhibitory concentrations of 12 nM for serotonin, 23 nM for norepinephrine, and 96 nM for dopamine in HEK 293 cells. This compound is pertinent for research applications exploring the modulation of monoaminergic systems and investigating potential therapeutic effects in mood disorders. -
D2R Antagonist
BRD5814 is a potent antagonist of the dopamine D2 receptor (D2R), a key target in the modulation of dopaminergic signaling. This compound demonstrates significant inhibitory activity, making it a valuable tool in research focused on schizophrenia and other neuropsychiatric disorders. Its application in studies of D2R-related pathways can aid in understanding the complex mechanisms underlying these conditions. -
Dopamine D4 Receptor Partial Agonist
FAUC-312 is a tetrahydropyrimidine that acts as a selective partial agonist of the dopamine D4 receptor, exhibiting a Ki value of 1.5 nM. This compound modulates dopaminergic signaling and has potential applications in researching neuropsychiatric disorders, including schizophrenia and attention deficit hyperactivity disorder (ADHD). Its specificity towards the D4 receptor allows for the exploration of receptor-specific pathways and therapeutic interventions. -
Chlorpromazine Active Metabolite
7-Hydroxychlorpromazine hydrochloride is the active metabolite of Chlorpromazine, primarily targeting dopamine receptors. This compound is known to increase prolactin levels and enhance dopamine turnover, exhibiting notable sedative effects. Research applications include studying psychosis and investigating its efficacy in inhibiting amphetamine-induced stereotyped behaviors in rodent models. -
Dopamine Agonist
PD 118440 is an orally active dopamine agonist that targets dopaminergic signaling pathways within the central nervous system. This compound demonstrates notable biological activity by inhibiting striatal dopamine synthesis and suppressing the firing of dopamine neurons. Additionally, PD 118440 has been shown to reverse Reserpine-induced depression in rodent models, making it a valuable tool for research in neuropharmacology and mood disorder studies. -
Dopamine Agonist
Lergotrile mesylate is a potent orally active dopamine agonist that functions primarily by activating dopamine receptors in the adenohypophysis, thereby inhibiting prolactin secretion. This mechanism contributes to its potential applications in the research of Parkinson's disease and related disorders. By modulating dopamine activity, Lergotrile mesylate serves as a valuable tool for exploring therapeutics targeting dopaminergic pathways. -
Dopamine Receptor Agonist
Disulergine is an ergot alkaloid that acts as a dopamine receptor agonist. It has been shown to inhibit prolactin secretion in rats and also suppress the release of growth hormone (GH). This compound is particularly relevant for research applications exploring the regulation of hormonal pathways and the physiological effects of dopamine receptor modulation. -
Central Dopamine Receptor Antagonist
Brl 20596 is a potent central dopamine receptor antagonist. This compound exhibits significant inhibitory activity at dopamine receptors, making it valuable for antipsychotic research. Its ability to modulate dopaminergic signaling can aid in the investigation of neuropsychiatric disorders related to dopamine dysregulation. -
DA2 Receptor Agonist
7-Hydroxy ropinirole bromide is a selective DA2 receptor agonist that demonstrates significant inhibitory effects on neurotransmitter release and sympathetic nerve responses. This compound, a derivative of N,N-di-n-propyldopamine (DPDA), has shown promise in isolated perfused rabbit ear artery models, making it a valuable tool for studying cardiovascular and neurological disorders. Its targeted mechanism of action underscores its relevance in exploring therapeutic interventions in these fields. -
CI-1007 Active Metabolite
PD-147693 is the active metabolite of the presynaptic dopamine autoreceptor agonist CI-1007, exhibiting antipsychotic activity akin to its parent compound. This reagent is utilized in neuropharmacological research to explore the mechanisms of dopaminergic signaling and evaluate potential therapeutic approaches for neuropsychiatric disorders. Its relevance extends to studies focused on dopamine receptor interactions and their implications in psychopharmacology. -
D3 Receptor Antagonist
(Rac)-GR218231 is a selective antagonist of the dopamine D3 receptor, exhibiting a pKi value of 8.9. This compound is valuable for studying the role of D3 receptors in various neurological and psychiatric disorders. Its pharmacological properties make it an important tool for research into dopamine-related pathways and potential therapeutic interventions. -
Antipsychotic Compound
A 23887 is a semirigid antipsychotic compound that primarily targets the dopamine D2 receptor. It exhibits significant affinity for this receptor, which is crucial for modulating dopaminergic signaling pathways. This compound is primarily utilized in research related to psychiatric disorders, particularly in the study of schizophrenia and other neuropsychiatric conditions. -
Stable Isotope
Ropinirole-d3 hydrochloride is a deuterium-labeled derivative of Ropinirole hydrochloride, functioning as a potent agonist for D2 and D3 dopamine receptors, with a Ki value of 29 nM for the D2 receptor. It exhibits pEC50 values of 7.4, 8.4, and 6.8 for human D2, D3, and D4 receptors, respectively, while showing no affinity for D1 receptors. This compound is primarily utilized in research related to dopamine receptor signaling and has potential implications for therapies targeting Parkinson's disease. -
Dopamine D2 Receptor Antagonist
ADR 851 free base is a potent antagonist of the dopamine D2 receptor, making it valuable for research applications focused on antiemetic effects. This compound demonstrates significant potential in modulating dopamine-related pathways, contributing to the understanding of various neurological and psychiatric disorders. Its utilization in experimental studies may provide insights into therapeutic strategies targeting nausea and vomiting. -
D1 Receptor Agonist
SKF-80723 acts as a selective agonist for the dopamine D1 receptor, playing a crucial role in neurotransmitter signaling. This compound is primarily utilized in neuroscience research, particularly in studies related to Parkinson's disease and dopaminergic dysfunction. Its activation of D1 receptors offers insights into potential therapeutic strategies for neurodegenerative conditions associated with dopaminergic signaling deficits. -
Dopamine Receptor Agonist
Aplindore fumarate is a partial agonist of the dopamine D2 receptor, primarily utilized in neurological research. This compound has shown potential in studies related to Parkinson's disease and schizophrenia, offering insights into dopaminergic signaling pathways. Its activity makes it a valuable tool for investigating therapeutic strategies and understanding the underlying mechanisms of these disorders. -
D3R agonist
7-Hydroxy-PIPAT is a selective agonist of the D3 dopamine receptor, exhibiting a high binding affinity with a Ki value of 0.99 nM. This compound is utilized in research to explore mechanisms related to dopaminergic signaling and may offer insights into the pathology of neuropsychiatric disorders. Its potent activity makes it a valuable tool for studying D3 receptor-mediated pathways in various biological contexts. -
Atypical Dopamine Agonist
S3608 is an atypical dopamine agonist that selectively activates dopamine receptors, contributing to enhanced locomotor activity. This compound has been shown to dose-dependently increase locomotor activity in rodent models, making it a valuable tool for studying dopaminergic signaling and its implications in neuropharmacology. S3608 can be utilized in research applications focused on movement disorders, addiction, and behavioral studies related to dopamine modulation. -
D4 Receptor Antagonist
Sonepiprazole mesylate is a selective D4 dopamine receptor antagonist that exhibits inhibition constants (Kis) of 3.6 nM for rD4-Dopamine and 10.1 nM for hD4.2-Dopamine, indicating potent activity at these targets. Additionally, it shows significantly lower affinity for rD2-Dopamine (5147 nM) and Histamine-H1 receptors (7430 nM). This compound is valuable for research applications focused on neurobiology, particularly in studies related to dopamine receptor signaling and its implications in psychiatric disorders. -
Dopamine D-2 Receptors Antagonist
A31472 is a potent antagonist of dopamine D-2 receptors, making it a valuable tool for studying the pharmacology of antipsychotic agents. Its mechanism of action is critical for exploring the underlying pathways associated with dopamine dysregulation. Researchers can utilize A31472 to investigate its effects on behavioral and neurochemical processes relevant to psychiatric disorders. -
Dopamine Antagonist
Clothixamide is a dopamine antagonist that primarily targets dopamine receptors in the central nervous system. It exhibits biological activity relevant to the modulation of dopaminergic signaling and is useful for investigating various psychiatric disorders, including schizophrenia and depression. Research applications include studying the effects of dopamine inhibition on behavior and neurotransmitter pathways. -
Dopamine Receptor Antagonist
Org-10490 is a potent antagonist of dopamine D1 and D2 receptors, primarily utilized in neurological and psychiatric research. It plays a critical role in studies related to disorders such as schizophrenia and bipolar disorder by modulating dopaminergic signaling pathways. Its efficacy in receptor inhibition makes Org-10490 valuable for investigating therapeutic strategies targeting dopamine-related conditions.
